These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 30739334)

  • 21. BRAF p.V600E status in epithelial areas of ameloblastoma with different histological aspects: Implications to the clinical practice.
    Sant'Ana MSP; Dos Santos Costa SF; da Silva MP; Martins-Chaves RR; Pereira TDSF; de Oliveira EM; Martínez Pedraza R; de Castro WH; Gomes CC; Gomez RS; Fonseca FP
    J Oral Pathol Med; 2021 May; 50(5):478-484. PubMed ID: 33377543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution.
    Owosho AA; Ladeji AM; Adebiyi KE; Olajide MA; Okoye ISI; Kehinde T; Nwizu NN; Summersgill KF
    Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3065-3071. PubMed ID: 33231757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of BRAF V600E mutation in odontogenic tumors by high-performance MALDI-TOF analysis.
    Togni L; Zizzi A; Mazzucchelli R; Santarelli A; Rubini C; Mascitti M
    Int J Oral Sci; 2022 Apr; 14(1):22. PubMed ID: 35468886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of BRAF V600E expression and disease-free survival in patients with ameloblastoma.
    Kunmongkolwut S; Chaisuparat R
    Int J Oral Maxillofac Surg; 2022 Aug; 51(8):1034-1042. PubMed ID: 34998647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. It was not possible to detect BRAF V600E mutation in circulating cell-free DNA from patients with ameloblastoma: A diagnostic accuracy study.
    Martins-de-Barros AV; da Costa Araújo FA; Barros AMI; Dos Santos EGF; Barbosa Neto AG; da Silva HAM; de Lima ELS; Muniz MTC; Neves RFSN; de Hollanda Valente RO; de Oliveira E Silva ED; de Vasconcelos Carvalho M
    J Oral Pathol Med; 2024 Apr; 53(4):258-265. PubMed ID: 38494749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High prevalence of BRAF V600E mutations in Korean patients with ameloblastoma: Clinicopathological significance and correlation with epithelial-mesenchymal transition.
    Oh KY; Cho SD; Yoon HJ; Lee JI; Ahn SH; Hong SD
    J Oral Pathol Med; 2019 May; 48(5):413-420. PubMed ID: 30889301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Whole exome sequencing and system biology analysis support the "two-hit" mechanism in the onset of Ameloblastoma.
    Shi Y; Li M; Yu Y; Zhou Y; Wang S
    Med Oral Patol Oral Cir Bucal; 2021 Jul; 26(4):e510-e517. PubMed ID: 33395399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing pathogenic mutations in dental follicles as an attempt to identify early events in odontogenic tumours tumourigenesis.
    Coura BP; de Resende TAC; de Menezes VCB; Bernardes VF; de Sousa SF; Diniz MG; Gomez RS; Gomes CC
    Arch Oral Biol; 2020 May; 113():104523. PubMed ID: 31543246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas.
    do Canto AM; da Silva Marcelino BMR; Schussel JL; Wastner BF; Sassi LM; Corrêa L; de Freitas RR; Hasséus B; Kjeller G; Junior CAL; Braz-Silva PH
    Clin Oral Investig; 2019 Feb; 23(2):779-784. PubMed ID: 29855709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAFV600E mutation in the diagnosis of unicystic ameloblastoma.
    Pereira NB; Pereira KM; Coura BP; Diniz MG; de Castro WH; Gomes CC; Gomez RS
    J Oral Pathol Med; 2016 Nov; 45(10):780-785. PubMed ID: 27084044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aberrant beta-catenin expression and adenomatous polyposis coli gene mutation in ameloblastoma and odontogenic carcinoma.
    Siriwardena BS; Kudo Y; Ogawa I; Tilakaratne WM; Takata T
    Oral Oncol; 2009 Feb; 45(2):103-8. PubMed ID: 18486530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas.
    Lapthanasupkul P; Laosuk T; Ruangvejvorachai P; Aittiwarapoj A; Kitkumthorn N
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Nov; 132(5):e180-e185. PubMed ID: 32665205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress towards personalized medicine for ameloblastoma.
    Gomes CC; Diniz MG; Gomez RS
    J Pathol; 2014 Apr; 232(5):488-91. PubMed ID: 24749150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Immunohistochemistry and DNA Sequencing for BRAF V600E Mutation Detection in Mandibular Ameloblastomas.
    da Silva Marcelino BMR; Parise GK; do Canto AM; Sassi LM; Sarmento DJS; Costa ALF; Hasséus B; Kjeller G; Schussel JL; Braz-Silva PH
    Appl Immunohistochem Mol Morphol; 2021 May-Jun 01; 29(5):390-393. PubMed ID: 33443847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF V600E expression in ameloblastomas-A 36-patient cohort from Helsinki University Hospital.
    Kelppe J; Thorén H; Ristimäki A; Haglund C; Sorsa T; Hagström J
    Oral Dis; 2019 May; 25(4):1169-1174. PubMed ID: 30811720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors affecting the accuracy of anti-BRAF V600E immunohistochemistry results in ameloblastomas.
    Chang JYF; Lu PH; Tseng CH; Wang YP; Lee JJ; Chiang CP
    J Oral Pathol Med; 2023 Apr; 52(4):342-350. PubMed ID: 36625499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of BRAF mutational status with clinical characteristics and survival outcomes of patients with ameloblastoma: the experience of 11 Italian centres.
    Bonacina R; Indini A; Massazza G; Rulli E; Gianatti A; Mandalà M;
    J Clin Pathol; 2022 Aug; 75(8):555-559. PubMed ID: 33827932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The molecular basis of odontogenic cysts and tumours.
    Gomes IP; Bastos VC; Guimarães LM; Gomes CC
    J Oral Pathol Med; 2023 Apr; 52(4):351-356. PubMed ID: 36629457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Research advances in the v-raf murine sarcoma viral oncogene homolog gene mutation in ameloblastoma].
    Yan XC; Sun LS; Dong ZW; You Z; Dong Q
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Jul; 53(7):500-502. PubMed ID: 29996373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation.
    Fernandes GS; Girardi DM; Bernardes JPG; Fonseca FP; Fregnani ER
    BMC Cancer; 2018 Sep; 18(1):887. PubMed ID: 30208863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.